Skip to main content
ROSSARI BIOTECH LIMITED logo

ROSSARI BIOTECH LIMITED — Investor Relations & Filings

Ticker · ROSSARI ISIN · INE02A801020 LEI · 335800R7XFRR8ZTHBQ25 BSE.NS Manufacturing
Open in API
Filings indexed 529 across all filing types
Latest filing 2022-11-07 Annual Report
Country IN India
Listing BSE.NS ROSSARI

About ROSSARI BIOTECH LIMITED

https://www.rossari.com/

Rossari Biotech Limited is a specialty chemicals manufacturer focused on providing sustainable and innovative solutions across diverse sectors. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals, and Animal Health and Nutrition. In the HPPC segment, it supplies essential ingredients for detergents, soaps, paints, and water treatment applications. Its textile division offers a comprehensive range of chemicals for the entire textile value chain, including pre-treatment, dyeing, and finishing processes. Additionally, the company provides high-quality feed additives and supplements for the poultry and livestock industries. Driven by robust research and development capabilities, Rossari Biotech emphasizes eco-friendly chemistry and customized formulations to meet specific client requirements. With advanced manufacturing facilities, the company serves a global clientele, maintaining a strong focus on operational excellence.

Recent filings

Filing Released Lang Actions
Newspaper Advertisements
Annual Report Classification · 75% confidence The document text is heavily redacted or corrupted, with many unintelligible characters and omitted images. However, the metadata indicates a document length of 15,000 characters, which is substantial. The presence of digital signatures and references to dates suggests an official filing. The text includes references to financial and corporate terms, but no clear indication of a specific report type such as an earnings release, interim report, or audit report. There is no clear mention of voting results, management changes, or capital updates. The document does not appear to be a short announcement or a certification letter. Given the length and the nature of the content, it is most consistent with a full Annual Report (10-K) or equivalent comprehensive yearly report. Since the document is lengthy and contains detailed content (albeit redacted), it is unlikely to be a mere announcement or a regulatory filing. Therefore, the best classification is Annual Report (10-K). Q2 2022
2022-11-07 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for Q2 and H1 FY23 of Rossari Biotech Limited. It contains summarized financial performance data such as revenues, EBITDA, PAT, and EPS for the quarter and half-year periods. The text includes management commentary on the results and business outlook. The document is about quarterly financial results but is presented as an announcement rather than a comprehensive interim or quarterly report with detailed financial statements and analysis. The length is about 7,305 characters, which is relatively short and typical for an earnings release. There is no indication of detailed financial statements or extensive analysis that would qualify it as an Interim/Quarterly Report (IR). Therefore, the document fits best as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Q2 2023
2022-11-05 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Rossari Biotech Limited Q2 & H1 FY23 Results Presentation November 5, 2022' and contains detailed financial data including revenue, EBITDA, PAT, segment-wise revenue, consolidated balance sheet, cash flows, and management commentary. It covers the quarterly and half-year financial performance for FY23, with comparative figures for previous periods. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a comprehensive interim or quarterly financial report, including actual financial statements and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2023
2022-11-05 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings Classification · 100% confidence The document text is extremely short (322 characters) and contains only digital signature information without any substantive content or financial data. There is no indication of a report, announcement, or detailed filing. Given the brevity and nature of the content, it does not fit any specific report category and is best classified as a Regulatory Filing (RNS), which serves as a fallback for miscellaneous filings without substantive content.
2022-11-05 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement dated November 5, 2022, from Rossari Biotech Limited regarding the outcome of a Board Meeting. It includes approval of unaudited financial results for the quarter and half year ended September 30, 2022, which are enclosed. The document also contains an Independent Auditor's Review Report on the interim standalone financial results, referencing Indian Accounting Standard 34 (Interim Financial Reporting). The financial data includes income, expenses, profit before tax, tax expense, and comprehensive income for the quarter and half year periods. The presence of unaudited financial results for a period shorter than a full fiscal year, along with the auditor's limited review report, clearly indicates this is an Interim / Quarterly Report. The document is substantive and contains actual financial statements and analysis, not merely an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2022-11-05 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 90% confidence The document is an announcement for a conference call scheduled on November 7, 2022, to discuss the Q2 FY23 earnings results of Rossari Biotech Limited. It includes dial-in details, a brief company description, and a disclaimer about forward-looking statements. There is no actual financial data or detailed discussion of results in the text; it is purely an invitation and information about the upcoming earnings call. Therefore, this document is a Call Transcript announcement or invitation, not the transcript itself. However, since the document is the announcement of the call and not the transcript, the best fitting category is Call Transcript (CT), as it relates directly to the earnings conference call event.
2022-11-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.